#drug trial
Related Stories (2)
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings - Reuters
Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings Reuters
June 29, 2026Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial - Reuters
Novo Nordisk's obesity drug CagriSema falls short against Eli Lilly's in trial Reuters
February 23, 2026Related Pages (2)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
news.google.com•June 30, 2026
Novo Nordisk’s obesity drug falls short against Eli Lilly’s in trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s tirzepatide in reducing
english.aaj.tv•February 24, 2026